Allspring Global Investments Holdings LLC Cuts Stake in Charles River Laboratories International, Inc. $CRL

Allspring Global Investments Holdings LLC lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,993,316 shares of the medical research company’s stock after selling 2,280 shares during the period. Charles River Laboratories International accounts for about 0.6% of Allspring Global Investments Holdings LLC’s investment portfolio, making the stock its 25th largest position. Allspring Global Investments Holdings LLC owned about 4.04% of Charles River Laboratories International worth $348,631,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Tema Etfs LLC bought a new stake in shares of Charles River Laboratories International in the fourth quarter worth about $26,000. Los Angeles Capital Management LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter worth about $42,000. Sfam LLC bought a new position in Charles River Laboratories International during the fourth quarter valued at approximately $43,000. Activest Wealth Management grew its holdings in Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after buying an additional 218 shares in the last quarter. Finally, Elyxium Wealth LLC purchased a new position in Charles River Laboratories International during the 4th quarter valued at approximately $46,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $229.08 on Friday. The company has a market cap of $11.03 billion, a P/E ratio of -60.93, a P/E/G ratio of 2.54 and a beta of 1.40. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The business’s 50 day moving average price is $191.82 and its 200-day moving average price is $186.50. Charles River Laboratories International, Inc. has a fifty-two week low of $144.26 and a fifty-two week high of $237.86.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The company had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.Charles River Laboratories International’s revenue was up 1.2% on a year-over-year basis. During the same period last year, the company earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

Insider Activity

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the completion of the sale, the director owned 31,596 shares of the company’s stock, valued at $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the topic of several recent research reports. BNP Paribas Exane set a $250.00 price objective on Charles River Laboratories International in a report on Wednesday, July 1st. Mizuho raised their target price on shares of Charles River Laboratories International from $192.00 to $230.00 and gave the company a “neutral” rating in a report on Monday. Barclays boosted their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Monday, April 13th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $220.75.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.